JOP20230018A1 - نظام منخفض الجرعة وصيغة لمركب 5-ميثيل-1، 2، 4-أوكساديازول-3-يل - Google Patents
نظام منخفض الجرعة وصيغة لمركب 5-ميثيل-1، 2، 4-أوكساديازول-3-يلInfo
- Publication number
- JOP20230018A1 JOP20230018A1 JOJO/P/2023/0018A JOP20230018A JOP20230018A1 JO P20230018 A1 JOP20230018 A1 JO P20230018A1 JO P20230018 A JOP20230018 A JO P20230018A JO P20230018 A1 JOP20230018 A1 JO P20230018A1
- Authority
- JO
- Jordan
- Prior art keywords
- compound
- oxadiazol
- formulation
- methyl
- low
- Prior art date
Links
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
- A61K31/44—Non condensed pyridines; Hydrogenated derivatives thereof
- A61K31/445—Non condensed piperidines, e.g. piperocaine
- A61K31/4523—Non condensed piperidines, e.g. piperocaine containing further heterocyclic ring systems
- A61K31/454—Non condensed piperidines, e.g. piperocaine containing further heterocyclic ring systems containing a five-membered ring with nitrogen as a ring hetero atom, e.g. pimozide, domperidone
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
- A61K31/44—Non condensed pyridines; Hydrogenated derivatives thereof
- A61K31/4427—Non condensed pyridines; Hydrogenated derivatives thereof containing further heterocyclic ring systems
- A61K31/4439—Non condensed pyridines; Hydrogenated derivatives thereof containing further heterocyclic ring systems containing a five-membered ring with nitrogen as a ring hetero atom, e.g. omeprazole
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/28—Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
Landscapes
- Health & Medical Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Engineering & Computer Science (AREA)
- Neurosurgery (AREA)
- Life Sciences & Earth Sciences (AREA)
- Animal Behavior & Ethology (AREA)
- General Health & Medical Sciences (AREA)
- Public Health (AREA)
- Veterinary Medicine (AREA)
- Medicinal Chemistry (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Biomedical Technology (AREA)
- Pharmacology & Pharmacy (AREA)
- Neurology (AREA)
- Organic Chemistry (AREA)
- Hospice & Palliative Care (AREA)
- Psychiatry (AREA)
- Chemical Kinetics & Catalysis (AREA)
- General Chemical & Material Sciences (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Epidemiology (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Heterocyclic Carbon Compounds Containing A Hetero Ring Having Nitrogen And Oxygen As The Only Ring Hetero Atoms (AREA)
Applications Claiming Priority (2)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US202063055362P | 2020-07-23 | 2020-07-23 | |
| PCT/US2021/042877 WO2022020663A1 (en) | 2020-07-23 | 2021-07-23 | Low dose regimen and formulation of a 5-methyl-1,2,4-oxadiazol-3-yl compound |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| JOP20230018A1 true JOP20230018A1 (ar) | 2023-01-23 |
Family
ID=77338898
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JOJO/P/2023/0018A JOP20230018A1 (ar) | 2020-07-23 | 2023-01-23 | نظام منخفض الجرعة وصيغة لمركب 5-ميثيل-1، 2، 4-أوكساديازول-3-يل |
Country Status (21)
| Country | Link |
|---|---|
| US (1) | US20230338349A1 (https=) |
| EP (1) | EP4185291B1 (https=) |
| JP (1) | JP2023535034A (https=) |
| KR (1) | KR20230043905A (https=) |
| CN (1) | CN116323604A (https=) |
| AR (1) | AR123031A1 (https=) |
| AU (1) | AU2021312894B2 (https=) |
| BR (1) | BR112023000975A2 (https=) |
| CA (1) | CA3186808A1 (https=) |
| CL (1) | CL2023000194A1 (https=) |
| CO (1) | CO2023000594A2 (https=) |
| DO (1) | DOP2023000009A (https=) |
| EC (1) | ECSP23005057A (https=) |
| ES (1) | ES3039536T3 (https=) |
| IL (1) | IL300023A (https=) |
| JO (1) | JOP20230018A1 (https=) |
| MX (1) | MX2023000993A (https=) |
| PE (1) | PE20231031A1 (https=) |
| PH (1) | PH12023550177A1 (https=) |
| TW (1) | TW202220650A (https=) |
| WO (1) | WO2022020663A1 (https=) |
Families Citing this family (1)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| CA3243602A1 (en) | 2022-02-03 | 2023-08-10 | Eli Lilly And Company | Regional Tau Imaging for the Diagnosis and Treatment of Alzheimer's Disease |
Family Cites Families (3)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| WO2018014331A1 (zh) * | 2016-07-22 | 2018-01-25 | 深圳市大富科技股份有限公司 | Usb金属管件加工设备及其上模板 |
| TWI654978B (zh) * | 2017-01-27 | 2019-04-01 | 美商美國禮來大藥廠 | 5－甲基－1,2,4－二唑－3－基化合物 |
| CA3107788A1 (en) * | 2018-07-31 | 2020-02-06 | Eli Lilly And Company | Combination of anti-tau antibody and oga inhibitor for treatment of diseases characterized by aberrant tau aggregation |
-
2021
- 2021-07-21 TW TW110126729A patent/TW202220650A/zh unknown
- 2021-07-21 AR ARP210102050A patent/AR123031A1/es unknown
- 2021-07-23 ES ES21755253T patent/ES3039536T3/es active Active
- 2021-07-23 PH PH1/2023/550177A patent/PH12023550177A1/en unknown
- 2021-07-23 JP JP2023504346A patent/JP2023535034A/ja active Pending
- 2021-07-23 PE PE2023000107A patent/PE20231031A1/es unknown
- 2021-07-23 BR BR112023000975A patent/BR112023000975A2/pt unknown
- 2021-07-23 CN CN202180063288.5A patent/CN116323604A/zh active Pending
- 2021-07-23 AU AU2021312894A patent/AU2021312894B2/en active Active
- 2021-07-23 CA CA3186808A patent/CA3186808A1/en active Pending
- 2021-07-23 WO PCT/US2021/042877 patent/WO2022020663A1/en not_active Ceased
- 2021-07-23 IL IL300023A patent/IL300023A/en unknown
- 2021-07-23 US US18/005,245 patent/US20230338349A1/en active Pending
- 2021-07-23 KR KR1020237005839A patent/KR20230043905A/ko active Pending
- 2021-07-23 EP EP21755253.8A patent/EP4185291B1/en active Active
- 2021-07-23 MX MX2023000993A patent/MX2023000993A/es unknown
-
2023
- 2023-01-19 CL CL2023000194A patent/CL2023000194A1/es unknown
- 2023-01-19 CO CONC2023/0000594A patent/CO2023000594A2/es unknown
- 2023-01-20 DO DO2023000009A patent/DOP2023000009A/es unknown
- 2023-01-23 JO JOJO/P/2023/0018A patent/JOP20230018A1/ar unknown
- 2023-01-23 EC ECSENADI20235057A patent/ECSP23005057A/es unknown
Also Published As
| Publication number | Publication date |
|---|---|
| EP4185291B1 (en) | 2025-07-09 |
| AU2021312894B2 (en) | 2025-09-11 |
| WO2022020663A1 (en) | 2022-01-27 |
| MX2023000993A (es) | 2023-03-01 |
| CO2023000594A2 (es) | 2023-01-26 |
| PE20231031A1 (es) | 2023-07-10 |
| CL2023000194A1 (es) | 2023-07-21 |
| CN116323604A (zh) | 2023-06-23 |
| ECSP23005057A (es) | 2023-02-28 |
| JP2023535034A (ja) | 2023-08-15 |
| EP4185291A1 (en) | 2023-05-31 |
| CA3186808A1 (en) | 2022-01-27 |
| IL300023A (en) | 2023-03-01 |
| TW202220650A (zh) | 2022-06-01 |
| AR123031A1 (es) | 2022-10-26 |
| KR20230043905A (ko) | 2023-03-31 |
| EP4185291C0 (en) | 2025-07-09 |
| BR112023000975A2 (pt) | 2023-02-07 |
| DOP2023000009A (es) | 2023-02-15 |
| PH12023550177A1 (en) | 2024-03-18 |
| US20230338349A1 (en) | 2023-10-26 |
| ES3039536T3 (en) | 2025-10-22 |
| AU2021312894A1 (en) | 2023-02-23 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| US20240041900A1 (en) | Glutamine antagonists for the treatment of cognitive deficits and psychiatric disorders | |
| NZ788543A (en) | Dimethyltryptamine derivatives and their use in psychedelic-assisted psychotherapy | |
| UY26025A1 (es) | Procedimiento para la preparacion de composiciones de celecoxib | |
| CN104203234B (zh) | 吡唑衍生物用于治疗慢性阻塞性肺病急性恶化的用途 | |
| JP2016532667A (ja) | ヒストンデアセチラーゼ阻害薬及び免疫調節薬の組み合わせ | |
| JP2020147597A (ja) | オートファジーの流れ及びホスホリパーゼｄ及びタウを含むタンパク質凝集体のクリアランスの活性化剤ならびにタンパク質症の治療方法 | |
| JOP20230018A1 (ar) | نظام منخفض الجرعة وصيغة لمركب 5-ميثيل-1، 2، 4-أوكساديازول-3-يل | |
| RU2019135261A (ru) | Фармацевтическая композиция, содержащая ингибитор pde9 | |
| BR112023025552A2 (pt) | Composições estabilizadas de apilimod e usos das mesmas | |
| BR112022008551A2 (pt) | Forma de dosagem farmacêutica de desintegração oral, e, processo para a preparação de uma forma de dosagem de desintegração oral | |
| JP2010514734A (ja) | 腸障害の治療のためのイソソルビドモノニトレート誘導体 | |
| JP2019507786A5 (https=) | ||
| JP2016528171A5 (https=) | ||
| JP2021512086A5 (https=) | ||
| BR112019024804A2 (pt) | compostos bicíclicos 5,6-fundidos e composições para o tratamento de doenças parasíticas | |
| RU2014147728A (ru) | Производное транс-2-деценовой кислоты и содержащее его лекарственное средство | |
| WO2016189406A1 (en) | Pharmaceutical composition of teriflunomide | |
| JP2018515507A5 (https=) | ||
| AU2014284304A1 (en) | Method of treating neurodegenerative disorders | |
| MX2019003720A (es) | Composiciones y metodos para tratar el mal de alzheimer y la enfermedad de parkinson. | |
| NZ788970A (en) | Methods for treating behavioral and psychological symptoms in patients with dementia | |
| RU2013139704A (ru) | Применение белка yb-1 и его фрагментов для изготовления лекарственных средств при лечении болезни альцгеймера | |
| WO2019109150A1 (en) | Methods of treating agitation | |
| JP2021521227A5 (https=) | ||
| ES2280150T1 (es) | Combinacion de fluconazol-tinidazol para el tratamiento de infecciones vaginales, composicion de la misma y preparacion y uso de la misma. |